NCT03441113
Extended Access of Momelotinib in Adults With Myelofibrosis
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 57 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 4 more changesShow less
- Eligibility criteria expanded, about 207 words
- Study completion pushed from Dec 11, 2026 to Dec 29, 2028
- Interventions modified
- Site details revised at 31 of 112 sites
- Minor Study sites: 224 to 112
- Primary and study completion dates: Dec 31, 2026 to Dec 11, 2026
- Notable Lead sponsor: Sierra Oncology LLC - a GSK company to GlaxoSmithKline
- Enrollment target: estimated 400 to confirmed 237
- Study sites: 113 to 224
- Primary and study completion dates: Dec 2026 to Dec 31, 2026
- Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv52
- Minor Study sites: 112 to 113v51
Show 41 earlier versionsHide 41 earlier versions
- Minor Study sites: 111 to 112v50
- Minor Study sites: 110 to 111v49
- Minor Study sites: 108 to 110v48
- Minor Study sites: 107 to 108v47
- Minor Study sites: 104 to 107v46
- Minor Study sites: 102 to 104v45
- Minor Study sites: 101 to 102v44
- Minor Study sites: 100 to 101v43
- Minor Study sites: 98 to 100v42
- Minor Study sites: 97 to 98v41
- Minor Study sites: 96 to 97v39
- Minor Study sites: 95 to 96v38
- Minor Study sites: 92 to 95v37
- Minor Study sites: 90 to 92v36
- Minor Study sites: 89 to 90v35
- Minor Study sites: 88 to 89v34
- Minor Study sites: 87 to 88v33
- Minor Study sites: 85 to 87v32
- Minor Study sites: 81 to 85v31
- Notable Primary and study completion dates: Dec 2024 to Dec 2026
- Study sites: 79 to 81
- Minor Study sites: 78 to 79v29
- Minor Study sites: 77 to 78v28
- Minor Study sites: 76 to 77v27
- Minor Study sites: 75 to 76v26
- Minor Study sites: 73 to 75v25
- Minor Study sites: 71 to 73v24
- Minor Study sites: 70 to 71v23
- Minor Study sites: 69 to 70v22
- Minor Study sites: 67 to 69v21
- Notable Primary and study completion dates: Jun 2020 to Dec 2024v19
- Notable Enrollment target: 200 to 400
- Study arms: 3 to 4
- Minor Study sites: 63 to 67v17
- Minor Study sites: 62 to 63v16
- Minor Study sites: 49 to 62v15
- Notable Lead sponsor: Gilead Sciences to Sierra Oncology LLC - a GSK companyv14
- Minor Study sites: 37 to 49v13
- Minor Study sites: 30 to 37v12
- Minor Study sites: 22 to 30v11
- Minor Study sites: 15 to 22v10
- Minor Study sites: 9 to 15v9
- Minor Study sites: 4 to 9v8
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
Drugs: Momelotinib
Sites
112 sites in 20 countries
United States 14, Italy 12, Spain 8, France 7, Germany 7, Hungary 7, Poland 7, Australia 6, Romania 6, South Korea 6, Israel 5, United Kingdom 5, Belgium 4, Bulgaria 4, Taiwan 4, Canada 3, Austria 2, Denmark 2, Singapore 2, Netherlands 1